Literature DB >> 11167148

Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma.

F Sandra1, T Mitsuyasu, N Nakamura, Y Shiratsuchi, M Ohishi.   

Abstract

Thirty-two ameloblastoma tissues were immunohistochemically studied using monoclonal anti-proliferating cell nuclear antigen (PCNA) and anti-Ki-67 antibodies. Positive cells were evaluated and analyzed in relation to the WHO classification, cytological pattern of the outer layer cell, clinical appearance, tumor location, radiographic appearance and patient's age. In regard to the cytological pattern of the outer layer cells, the basal cell type had significantly higher PCNA and Ki-67 (P<0.05) labeling indices than the cuboidal cell type. The solid type had significantly higher PCNA and Ki-67 (P<0.05) labeling indices than the cystic and the mixed type. The labeling index of the younger patient was found to be the lowest, the middle age was in the middle and the older patient was the highest. These results indicated that the proliferating activities of ameloblastomas are quite variable, and the evaluations of Ki-67 and PCNA seem to be good indicators to assess the proliferating activity of each type of ameloblastomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167148     DOI: 10.1016/s1368-8375(00)00079-8

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  19 in total

1.  EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence.

Authors:  Azza Abdel-Aziz; Maha M Amin
Journal:  Diagn Pathol       Date:  2012-02-02       Impact factor: 2.644

2.  Basal cell ameloblastoma: a rare histological variant of an uncommon tumor.

Authors:  Meela Sridhar; L Raja Bhaskar Reddy; Sagar Kharat; B S Mahesh; Lakshmi Gandi; Ashish Mahendra; Pankhuri Nigam; Parveen Grewal
Journal:  Niger J Surg       Date:  2015 Jan-Jun

3.  Immunohistochemistry of Five Molecular Markers for Typing and Management of Ameloblastomas: A Retrospective Analysis of 40 Cases.

Authors:  Thasvir Singh; Arun Chandu; John Clement; Christopher Angel
Journal:  J Maxillofac Oral Surg       Date:  2016-06-02

4.  Role of podoplanin expression in deciding the invasive potential of ameloblastoma - A retrospective IHC study.

Authors:  Sindhu M Ganvir; Pratima G Khobragade; Swati A Bamane; Ramnivas Kumavat; Amit Dalmia
Journal:  J Oral Biol Craniofac Res       Date:  2016-07-14

5.  Locally infiltrative ameloblastic fibroma in a rhesus macaque (Macaca mulatta) with characterizations of its proliferating activity and biological behavior.

Authors:  David X Liu; Lara A Doyle; Mostafa T Bouljihad; Peter J Didier; Margaret H Gilbert; Xiaolei Wang; Bapi Pahar; Rudolf P Bohm; Ronald S Veazey; Andrew A Lackner
Journal:  J Vet Diagn Invest       Date:  2012-05       Impact factor: 1.279

Review 6.  Analysis of the 100 most cited articles on ameloblastoma.

Authors:  Ricardo Grillo
Journal:  Oral Maxillofac Surg       Date:  2022-06-02

7.  CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.

Authors:  Yong-kang Ye; Xue-cheng Bi; Hui-chan He; Zhao-dong Han; Qi-shan Dai; Yu-xiang Liang; Guo-hua Zeng; Wei-jun Qin; Zhi-nan Chen; Wei-de Zhong
Journal:  Clin Exp Med       Date:  2010-01-13       Impact factor: 3.984

8.  Prognostic and proliferative evaluation of ameloblastoma based on radiographic boundary.

Authors:  Yi Li; Bo Han; Long-Jiang Li
Journal:  Int J Oral Sci       Date:  2012-02-24       Impact factor: 6.344

9.  A comparative immunohistochemical study of Ki-67 and Bcl-2 expression in solid ameloblastoma and adenomatoid odontogenic tumor.

Authors:  Sayed Mohammad Razavi; Sayed Hosein Tabatabaie; Ali Tavakoli Hoseini; Ehsan Tavakoli Hoseini; Arezu Khabazian
Journal:  Dent Res J (Isfahan)       Date:  2012-03

10.  Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors.

Authors:  Ronell Bologna-Molina; Adalberto Mosqueda-Taylor; Nelly Molina-Frechero; Ana-Dolores Mori-Estevez; Guillermo Sánchez-Acuña
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.